• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • QED-C
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Bios September 8, 2021

Gita Shankar

Director, Formulations R&D, Pharmaceutical Sciences

Gita Shankar, Ph.D., has an extensive background in pharmaceutics, biochemistry, polymer chemistry, and drug delivery. At SRI, she directs early stage preformulation of discovery compounds, preclinical formulation, and clinical product development for small molecules and biologics.

Shankar has supervised formulation development of drug product programs for more than 20 Investigational New Drug (IND) candidates and is an inventor on five oral formulation patents. One of her inventions for oral formulation of vancomycin has been successfully licensed for development as a planned treatment of methicillin-resistant staphylococcus aureus (MRSA).

She holds an Exemptee Certificate as a Manufacturer of Clinical Drugs, issued by the California Pharmacy Board. She is a member of the American Association of Pharmaceutical Sciences, Controlled Release Society and a nominated member of Radiation Research Society.

Shankar received her Ph.D. in polymer chemistry and drug delivery from the Center for Biomedical Engineering, Indian Institute of Technology, New Delhi, India. In addition, she holds a second Ph.D. in biochemistry and molecular biology from Oregon Health Sciences University.

Recent publications

more +
Monocyte Chemotactic Protein-Induced Protein 1 and 4 Form a Complex but Act Independently in Regulation of Interleukin-6 mRNA Degradation (12/1/2015) - Here we report that MCPIP1 interacts with MCPIP4 to form a protein complex but they act independently in regulation of…
SR-2P vaginal microbicide gel provides protection against herpes simplex virus 2 when administered as a combined prophylactic and postexposure therapeutic (9/1/2015) - Here, we show that a dose of SR-2P administered 24 h prior to infection provides some protection against the virus,…
Formulation Approaches to Improving the Delivery of an Antiviral Drug with Activity against Seasonal Flu (3/1/2015) - The main objective of the present study was to develop formulations of noscapine hydrochloride hydrate with enhanced solubility and bioavailability…

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2022 SRI International